Submission Deadline 06/22/2026
Fiscal Capacity $5,013
| Opportunity Number | CDC-RFA-JG-26-0125 |
|---|---|
| Agency | HHS-CDC-GHC |
| Application Deadline | 06/22/2026 |
| Award Amount | $5,013 |
| Status | Posted |
| Sector | Health |
| Cost Sharing | Not Required |
Fiscal Parameters & Taxonomy
Authority HHS-CDC-GHC
Status Posted
Who Can Apply
Small businesses Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Native American tribal governments (Federally recognized) For profit organizations other than small businesses Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" City or township governments State governments Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities County governments Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Eligibility Intelligence
See the official NOFO for full eligibility requirements.
Program Description
The Award Ceiling for Year 1 is 0 (none). CDC anticipates an Approximate Total Fiscal Year Funding amount of $3,000,000 for Year 1, subject to the availability of funds.The purpose of this NOFO is to reduce TB-related morbidity and mortality in India, the Philippines, and Vietnam by strengthening:• TB case finding, including linked activities such as screening, testing, and diagnostic evaluation.• TB prevention, including TB preventive treatment (TPT).• TB treatment, including linkage and improved treatment regimens, as appropriate.• Surveillance, through adopting, evaluating, and expanding innovative approaches.Activities implemented will focus on:• Expanding and improving diagnosis of TB infection and TB disease, including early and asymptomatic TB as well as drug-resistant or multidrug-resistant TB. This will be done by using and evaluating innovative screening and diagnostic methods and scaling up evidence-based approaches. • Improving TPT outcomes for all individuals at high risk of developing TB disease and improving TB treatment outcomes of individuals with TB disease, including those with drug-resistant or multidrug-resistant TB. This will be done by using new, shorter, and better-tolerated treatment regimens.• Strengthening TB surveillance for data-driven decision making, program planning, and public health action.Asia carries the highest burden of TB and drug-resistant or multidrug-resistant TB globally. This NOFO will focus on activities in India, the Philippines, and Vietnam because they are three of the top four countries contributing to the TB burden in the U.S. This aligns with the America First Global Health Strategy.
CFDA Programs
93.494 Global Tuberculosis:Developing,Evaluating,Implementing Evidence-based and Innovative Approaches to Find, Cure, and Prevent Tuberculosis Globally
Agency Contact
Related Intelligence Guides
In-depth editorial guides covering this agency's programs, eligibility requirements, and application strategies.